Ovid Therapeutics (OVID) Cash from Operations (QoQ) (2016 - 2026)
Ovid Therapeutics (OVID) Cash from Operations (QoQ) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 472.39 Bn | 467.60 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.08 Bn | 114.83 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn |
| 10 | Ovid Therapeutics | 120.41 Mn | -35.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.98% |
| Dec 31, 2025 | 19.12% |
| Sep 30, 2025 | -166.10% |
| Jun 30, 2025 | 53.11% |
| Mar 31, 2025 | -2.72% |
| Dec 31, 2024 | 33.31% |
| Sep 30, 2024 | -5.28% |
| Jun 30, 2024 | 14.57% |
| Mar 31, 2024 | -40.09% |
| Dec 31, 2023 | -18.49% |
| Sep 30, 2023 | 14.13% |
| Jun 30, 2023 | 3.35% |
| Mar 31, 2023 | -32.00% |
| Dec 31, 2022 | 27.62% |
| Sep 30, 2022 | 4.61% |
| Jun 30, 2022 | 33.84% |
| Mar 31, 2022 | -67.41% |
| Dec 31, 2021 | -10.36% |
| Sep 30, 2021 | 44.01% |
| Jun 30, 2021 | -112.07% |